Study wrapper · #1026
Pharmacologic Treatments for MASLD: A Review of Efficacy and Safety Considerations.
Newsome JS The Journal of pharmacy technology : jPT. 2026.
DOI: 10.1177/87551225261466571PubMed: 42483637
Editor's note
A narrative review of pharmacologic options for MASLD/MASH in which semaglutide is highlighted, alongside resmetirom, as having among the most consistent evidence for histologic improvement including fibrosis reduction. As a narrative review of eighteen sources, it summarizes rather than pools existing trial data. It offers a useful positioning of semaglutide within the broader metabolic liver disease treatment landscape.
Plain-language abstract
This review compares drug options for fatty liver disease and reports that semaglutide, alongside resmetirom, has the most consistent evidence for improving liver inflammation and fibrosis. Other agents showed more limited or mixed results.
Related coverage
Weak / none
A qualitative study exploring experiences about using semaglutide for weight loss in a rural setting in Denmark - 'she is probably on the meds'.
Scandinavian journal of primary health caren=——2026
Mixed
GLP-1 receptor agonists in stroke prevention: a narrative review on emerging therapeutic frontiers.
Annals of medicinen=——2026
Weak / none
Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.
Journal of medical economicsn=——2026